Biogen Idec (BIIB)
Biogen Idec Cash and ST Investments: 1.277B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BIIB Cash and ST Investments Rankings
| Overall | 90th percentile | 419 of 4365 |
| Sector | 93rd percentile | 31 of 504 in Healthcare |
| Industry | 97th percentile | 4 of 159 in Biotechnology |
BIIB Cash and ST Investments Range, Past 5 Years
| Minimum | 671.35M | Sep 2007 |
| Maximum | 1.803B | Jun 2007 |
| Average | 1.294B |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these BIIB related companies
BIIB News
Wondering Which Stocks to Sell? There’s a List and We Explain How to Read It http://stks.co/3ysW $NFLX $PCS $EA $BIIB $CBS $COG $DF
about 3 days ago by ycharts
about 3 days ago by ycharts
$BIIB http://stks.co/3tiV Daily CCI diveregence and reached target today under 20sma daily support http://stks.co/3tiW
about 10 days ago by xpertstocktrader
about 10 days ago by xpertstocktrader
New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of Medicine
May 17, 3:40PM Business Wire
May 17, 3:40PM Business Wire
$BIIB http://stks.co/3sIv partials at 10sma daily support and rest to entry price. http://stks.co/3sIw
about 11 days ago by xpertstocktrader
about 11 days ago by xpertstocktrader
$BIIB http://stks.co/3sD3 BIIB short under 136.10, stop above 138. Swing ods and good for 50% risk http://stks.co/3sD4
about 11 days ago by xpertstocktrader
about 11 days ago by xpertstocktrader
$BIIB http://stks.co/3s58 Idea is to watch CCI divergence and initial move down http://stks.co/3s59
about 11 days ago by xpertstocktrader
about 11 days ago by xpertstocktrader
RT @upsidetrader NEW POST: IS BIG BIOTECH READY TO FAIL? http://stks.co/3rgZ $IBB $CELG $SPX, $QQQ $BIIB $ALXN
about 11 days ago by packerfan48051
about 11 days ago by packerfan48051
NEW POST: IS BIG BIOTECH READY TO FAIL? http://stks.co/3reR $IBB $CELG $SPX, $QQQ $BIIB $ALXN
about 11 days ago by upsidetrader
about 11 days ago by upsidetrader
RT@Fibline $BIIB think thats a piece of $FBT- and $IBB@gregharmon mentioned yesterday. Report back tom
about 12 days ago by CaptainJohn
about 12 days ago by CaptainJohn
$BIIB http://stks.co/3qT9 Cont.'s to act well & orderly. Would not chase here. If it gets a pullback worth a try. Nice volume.
about 12 days ago by Fibline
about 12 days ago by Fibline
$MDVN $ARNA $ARIA $BIIB Noticed a bunch of pharma setting up over the weekend. I see why now.
about 14 days ago by Fibline
about 14 days ago by Fibline
$BIIB http://stks.co/3oWF Odds for new high and run to $140 target area - http://stks.co/3oWG
about 14 days ago by xpertstocktrader
about 14 days ago by xpertstocktrader
New AVONEX® Dosing Innovations for People with Multiple Sclerosis Now Available in US
May 14, 8:00AM Business Wire
May 14, 8:00AM Business Wire
RT@Fibline Excellant! or if chicken $FBT has litle over 5% of $BIIB both look great #drugs #getinmybelly :>)
about 15 days ago by CaptainJohn
about 15 days ago by CaptainJohn
$BIIB http://stks.co/3nbt "Stairsteps to Promise Land" or "Biotech Hand Grenade?". Like this set up.
about 15 days ago by Fibline
about 15 days ago by Fibline
$BIIB http://stks.co/3n5z BIIB at 137.50 resistance area..good for partials and rest for $140 http://stks.co/3n60
about 17 days ago by xpertstocktrader
about 17 days ago by xpertstocktrader
Goldman Sachs Said Biogen's (BIIB) BG-12 Acceptance Should Alliaate Concerns
May 10, 12:26PM Street Insider
May 10, 12:26PM Street Insider
US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review
May 09, 4:05PM Business Wire
May 09, 4:05PM Business Wire
UBS Maintains a 'Buy' on Biogen (BIIB); Core Franchise Support Valuation; Pipeline Provides Upside Risk
May 09, 12:38PM Street Insider
May 09, 12:38PM Street Insider
Biogen Idec to Present at the Deutsche Bank 37th Annual Healthcare Conference
May 02, 5:22PM Business Wire
May 02, 5:22PM Business Wire
Goldman Sachs Maintains Bullish Stance on Biogen (BIIB), Sees Room for Significant Upside
May 02, 7:55AM Street Insider
May 02, 7:55AM Street Insider
Baird Maintains a 'Neutral' on Biogen (BIIB); Still Prefer the Sidelines as Pipeline Remains The Focus
May 01, 3:58PM Street Insider
May 01, 3:58PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BIIB | 131.56 | -0.09 | -0.07% | 31.41B |
| BIG | 37.30 | +1.55 | +4.34% | 2.469B |
| BIF | 5.73 | +0.01 | +0.17% | |
| BIDZ | 0.76 | +0.01 | +0.66% | 13.97M |
| BDN | 11.29 | -0.07 | -0.62% | 1.611B |
| BDMS | 16.95 | -0.04 | -0.23% | 31.19M |
| BDL | 7.30 | +0.11 | +1.53% | 13.58M |
| BDJ | 7.16 | +0.02 | +0.28% | |
| BDGE | 19.78 | +0.00 | +0.00% | 167.54M |
| BDE | 9.14 | +0.09 | +0.99% | 280.42M |